MOA Life Plus Co. Ltd.
Financials
Valuation Metrics
MOA Life Plus Co. Ltd.'s Market Cap is ₩181B. At end of 2025 it was ₩748B. Ranked #2346 of 2,436 in KR market (top 96%), #1567 of 1,649 on KOSDAQ (top 95%), #229 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 98%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 18.13B KRW | KR#2,346/2,436 Sec#229/234 |
| Revenue | 10.45B KRW | KR#2,282/2,436 Sec#176/234 |
| Net Income | -12.81B KRW | KR—/2,436 Sec—/234 |
| Total Assets | 43.38B KRW | KR#2,242/2,436 Sec#205/234 |
| Net Assets | 31.99B KRW | KR#2,144/2,436 Sec#189/234 |
| Employees | 59 | KR#1,955/2,436 Sec#172/234 |
| Value | ||
| P/B | 0.57x | KR#925/2,436 Sec#42/234 |
| P/S | 1.73x | KR#1,746/2,436 Sec#99/234 |
| FCF Yield | -33.52% | KR—/2,436 Sec—/234 |
| Profitability | ||
| ROE | -40.05% | KR#2,228/2,436 Sec#187/234 |
| ROA | -29.53% | KR#2,297/2,436 Sec#197/234 |
| Op. Margin | -65.19% | KR#2,269/2,436 Sec#165/234 |
| Revenue Growth | -24.70% | KR#2,113/2,436 Sec#192/234 |
| Financial Health | ||
| Debt Ratio | 135.62% | KR#953/2,436 Sec#113/234 |
| Total Debt | 14.73B KRW | KR#1,485/2,436 Sec#131/234 |
| FCF | -6.08B KRW | KR#1,554/2,436 Sec#122/234 |
| Cash | 3.59B KRW | KR#2,105/2,436 Sec#195/234 |
| Current Ratio | 1.99x | KR#960/2,436 Sec#111/234 |
| Performance | ||
| 1Y Return | -75.34% | KR#2,381/2,436 Sec#230/234 |
| 1M Return | 14.97% | KR#186/2,436 Sec#12/234 |
| From 52W High | -80.28% | KR#2,354/2,436 Sec#220/234 |
| 1Y MDD | -82.77% | KR#2,340/2,436 Sec#224/234 |
| Trading | ||
| Volume | 419,318 shares | KR#317/2,436 Sec#37/234 |
| Foreign Own. | 1.37% | KR—/2,436 Sec—/234 |
| Per Share | ||
| EPS | -326 KRW | KR—/2,436 Sec—/234 |
| BPS | 759 KRW | KR#2,342/2,436 Sec#217/234 |
Company Info
Established in 1999 based on poly-gamma-glutamic acid source technology, the company is a bio new drug development firm listed on KOSDAQ in 2016. Utilizing HumaMAX and MucoMAX platforms, it focuses on new drug development and operates in health functional foods, functional cosmetics, pet care, and pharmaceutical distribution. The company holds a pipeline for rare disease treatments and manufactures and distributes health functional foods and functional cosmetics using immune-boosting functional ingredients.